PTO/SB/08A (08-03)

LEM

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/809,312

Filing Date 03/24/04

First Named Inventor Lloyd A. Greene
Art Unit 1636

Examiner Name to be assigned Laura McG. L

Attorney Docket Number | 5199-69

**U. S. PATENT DOCUMENTS** Examiner **Document Number** Publication Date Name of Patentee or Pages, Columns, Lines, Where foitials\* MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Number-Kind Code<sup>2</sup> (# known) Figures Appear <sup>US-</sup> 6,278,039 08-21-01 Johnson, et al. US- 2002/0006664 01-17-02 Sabatini, et al. US-US-US-US-US-US-US-US-US-US US-US-US-UŞ-

		FORE	IGN PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°
AM		WO99/32619	07-01-99	Fire, et al.		
Mn.		WO01/29058	04-26-01	Mello, et al.		
SM		WO01/68836	09-20-01	Beach, et al.		
ZM.		WO01/96584	12-20-01	Mushegian,etal.		

Examiner Signature	Laura	M Gillen	Date Considered	3/22/2006
*FVALUED	1 20 1 27 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	ite for form 1449/PTO			Complete if Known			
0000				Application Number	10/809,312		
INF	ORMATION	N DIS	SCLOSURE	Filing Date	03/24/04		
STA	ATEMENT I	BY A	PPLICANT	First Named Inventor	Lloyd A. Greene		
	(Use as many sh			Art Unit	1636		
	Use as many sn	eets as i	iecessary)	Examiner Name	to be assigned Laura McGillem		
Sheet	1	of	12	Attorney Docket Number	5199-69		

		NON PATENT LITERATURE DOCUMENTS										
	Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²								
3	Am		Ahmed et al., BDNF enhances the differentiation but not the survival of CNS stem cell-derived neuronal precursors.									
	SIM		J. Neurosci., 15: 5765-5778, 1995									
	SIM		Angelastro et al., Identification of diverse nerve growth factor-regulated genes by serial analysis of gene expression (SAGE) profiling. 2000									
	SM		Proc. Natl. Acad. Sci. USA, 97: 10424-10429, 2000	·								
	Sten		Angelastro et al., Characterization of a novel isoform of caspase-9 that inhibits apoptosis.									
	SM	•	J. Biol. Chem., 276: 12190-12200, 2001									
	HM		Ashrafi et al., Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes.									
	My	1. 4.	Nature, 421: 268-272, 2003									

Examiner	D -m 1	. 00	Date	2/22/
Signature	Lama Most	cen	Considered	312212006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substib	ite for form 1449/PTO			Complete if Known			
000300				Application Number	10/809,312		
INF	ORMATION	DIS	CLOSURE	Filing Date	03/24/04		
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Lloyd A. Greene		
				Art Unit	1636		
	(Use as many she	ets as n	iecessary)	Examiner Name	to be assigned Laura McG. LEM		
Sheet	2	of	12	Attorney Docket Number	5199-69		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
4M		Barco et al., Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture.	
An,		Cell, 108: 689-703, 2002	
An		Bhatia, AC133 expression in human stem cells.	
Lin		Leukemia, 15: 1685-1688, 2001	
The		Bieri et al., Abnormal nerve conduction studies in mice expressing a mutant form of the POU transcription factor, SCIP.	
Sm		J. Neurosci. Res., 50: 821-828, 1997	
MM;		Billy et al., Specific interference with gene expression induced by long, double-strand RNA in mouse embryonal teratocarcinoma cell lines.	
pn		Proc. Natl. Acad. Sci. USA, 98: 14428-14433, 2001	
			<u> </u>

Examiner Signature	Laura	Wille	Date Considered	3/22/2006
0.5.0.0				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a velid OMB control over the

Substitu	ite for form 1449/PTO			Complete if Known			
<b>3003</b> 00	10 10 10 11 14 37 10			Application Number	10/809,312		
INF	ORMATION	DIS	CLOSURE	Filing Date	03/24/04		
STA	ATEMENT I	BY A	PPLICANT	First Named Inventor	Lloyd A. Greene		
	(the en many sh			Art Unit	1636		
	(Use as many sh	eers as r	iecessary)	Examiner Name	tabe assigned LAURA MCGILLEM		
Sheet	3	of	12	Attorney Docket Number	5199-69		

	NON PATENT LITERATURE DOCUMENTS										
	Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²							
	£M.		Burstein and Greene, Evidence for RNA synthesis-dependent and –independent pathways in stimulation of neurite outgrowth by nerve growth factor.								
	An		Proc. Natl. Acad. Sci. USA, 75: 6059-6063, 1978								
t roude	d _		Cottrell et al., Silence of the strands: RNA interference in eukaryotic pathogens.	·							
corsi	Jaret		Trends Microbiol., 11: 37-43, 2003 ()//A)								
	Im		Dawson and Ginty, CREB family transcription factors inhibit neuronal suicide.								
•	Sm		Nat. Med., 8: 450-451, 2002								
	H		Dicicco-Bloom et al., The PACAP ligand/receptor system regulates cerebral cortical neurogenesis.								
	Pr		Ann. N. Y. Acad. Sci., 865: 274-289, 1998								

Examiner Date Signature Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	der the Paperwork Red te for form 1449/PTO	uction A	d of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control number.  Complete if Known
300500	ite iorioriii 14432710			Application Number	10/809,312
INF	ORMATION	DIS	CLOSURE	Filing Date	03/24/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Lloyd A. Greene
	(Use as many she	ote se n	ocoesan)	Art Unit	1636
	(USB as many sm	eta ea n	ecessary)	Examiner Name	to be assigned LAURA McGILLEM
Sheet	4	of	12	Attorney Docket Number	5199-69

	NON PATENT LITERATURE DOCUMENTS									
	Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²						
	Th		Escobar et al., RNAi-mediated oncogene silencing confers resistance to crown gall tumorigenesis.							
	Ha		Proc. Natl. Acad. Sci. USA, 98: 13437-13442, 2001							
,	Sa		Finkeiner et al., CREB: a major mediator of neuronal neurotrophin responses.							
	Im		Neuron, 19: 1031-1047, 1997.							
	SIM		Fukumitsu et al., Simultaneous expression of brain-derived neurotrophic factor and neurotrophin-3 in Cajal-Retzius, subplate and ventricular							
•	Am		progenitor cells during early development stages of the rat cerebral cortex.							
•	Am		Neuroscience, 84: 115-127, 1998,							
	Sh		Gage, F.H., Mammalian neural stem cells.							
	My		Science, 287: 1433-1438, 2000							
	,									

Examiner	I Tolle	Date	2/22/2-
Signature	Jama Meste	Considered	3/22/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ite for form 1449/PTO				Complete if Known
00000				Application Number	10/809,312
INF	ORMATIO	N DIS	CLOSURE	Filing Date	03/24/04
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	Lloyd A. Greene
	(Use as many sh			Art Unit	1636
	(Ose as many sn	ioets as n	lecessary)	Examiner Name	tabe assigned LAURA McGTLLEY
Sheet	5	of	12	Attorney Docket Number	5199-69

					ı
			NON PATENT LITERATURE DOCUMENTS		
	Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	Sh		Ghosh and Greenberg, Distinct roles for bFGF and NT-3 in the regulation of cortical neurogenesis.	·	
	Th		Neuron, 15: 89-103, 1995 •		
	4h		Greene et al., Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.		
	Sm		Proc. Natl. Acad Sci. USA, 73: 2424-2428, 1998.	·	
θ	•		Greene et al., Culture and Experimental Use of the PC12 Rat Pheochromocytoma Cell Line. In: Culturing Nerve Cells, 2nd ed., Goslin, G.K., ed.		L
عر			(Cambridge, MA: The MIT Press, 1998) pp. 161-187.		
	<i>An</i>		Gunning et al., Differential and synergistic actions of nerve growth factor and cyclic AMP in PC12 cells.		
	Iln		J. Cell Biol., 89: 240-245, 1981.		
	Th		Hansen et al., Mouse Atf5: molecular cloning of two novel mRNAs, genomic organization, and odorant sensory neuron localization.		
	fh		Genomics, 80: 344-350, 2002		

Examiner Signature Fama Modelly	Date Considered	3/22/2006
---------------------------------	--------------------	-----------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substib	ite for form 1449/PTO				Complete if Known
Cooduit				Application Number	10/809,312
INF	ORMATIO	N DIS	CLOSURE	Filing Date	03/24/04
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Lloyd A. Greene
	(Use as many st			Art Unit	1636
	lose as many sr	16612 92 1	ecessary)	Examiner Name	to be assigned. TAURI Mc 6. LIEN
Sheet	6	of	12	Attorney Docket Number	5199-69

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ť
<i>fm</i>		Julius et al., Q vectors, bicistronic retroviral vectors for gene transfer.	
Am		Biotechniques, 28: 702-708, 2000	
AM		Kintner, C., Neurogenesis in embryos and in adult neural stem cells.	
Am		J. Neurosci., 22: 639-643, 2002	
Am		Krylov et al., Extending dimerization interfaces: the bZIP basic region can form a coiled coil.	
An ,		EMBO J., 14: 5329-5337, 1995	
M		Kukekov et al., A nestin-negative precursor cell from the adult mouse brain gives rise to neurons and glia.	
Sh		Glia, 21: 399-407, 1997 (N/A)	
The		Kukekov et al., Multipotent stem / progenitor cells with similar properties arise from two neurogenic regions of adult human brain.	
m		Exp. Neurol., 156: 333-344, 1999	

Examiner	1 2 1 1	Date	7//-
Signature	Jamo Wille	Considered	13/23/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB contains.

Substitu	te for form 1449/PTO			Complete if Known		
300300	10 10 10 11 14 10 10 10 10 10 10 10 10 10 10 10 10 10			Application Number	10/809,312	
INF	ORMATION	N DIS	SCLOSURE	Filing Date	03/24/04	
STA	ATEMENT I	BY A	PPLICANT	First Named Inventor	Lloyd A. Greene	
	(the en many sh		-	Art Unit	1636	
	(Use as many sh	eeus as i	recessary)	Examiner Name	to be assigned LAUNA McGILLER	
Sheet	7	of	12	Attorney Docket Number	5199-69	

		NON DATENT ATTENDATION OF THE PROPERTY.	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
#A		Laywell et al., Multipotent neurospheres can be derived from forebrain subependymal zone and spinal cord of adult mice after protracted	
IM		postmortem intervals.	
M		Exp. Neurol., 156: 430-433, 1999 .	
Hr		Laywell et al., Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain.	
Th		Proc. Natl. Acad. Sci. USA, 97: 13883-13888, 2000,	
M		Lee et al., Posttranslational modification of class III beta-tubulin.	·
Ha		Proc. Natl. Acad. Sci. USA, 87: 7195-7199, 1990	
Th		Lendahl et al., CNS stem cells express a new class of intermediate filament protein.	
4m		Cell, 60: 585-595, 1990	

Examiner		mille Que	Date	7/22/200
Signature	Lama	Midellen	Considered	3/23/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Subatih	ste for form 1449/PT	· · · · · · · · · · · · · · · · · · ·			Complete if Known
300300	3.6 101 101111 1448/F1			Application Number	10/809,312
INF	ORMATIC	N DIS	CLOSURE	Filing Date	03/24/04
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	Lloyd A. Greene
				Art Unit	1636
	(Use as many	sneets as r	iecessary)	Examiner Name	to be assigned LAURA McGILLEM
Sheet	8	of	12	Attorney Docket Number	5199-69

	-	NON PATENT LITERATURE DOCUMENTS	•
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Am		Li et al., Neuronal differentiation of precursors in the neocortical ventricular zone is triggered by BMP.	
Am		J. Neurosci., 18: 8853-8862, 1998	
Ah		Lonze et al., Apoptosis, axonal growth defects, and degeneration of peripheral neurons in mice lacking CREB.	
M		Neuron, 34: 371-385, 2002	
M		Lu et al., The herpesvirus transactivator VP16 mimics a human basic domain leucine zipper protein, luman, in its interaction with HCF.	
th		J. Virol., 72: 6291-6297, 1998	
Sh		Mendelsohn et al., Stromal cells mediate retinoid-dependent functions essential for renal development.	
 Am		Development, 126: 1139-1148, 1999	
Th		Moitra et al., Life without white fat: a transgenic mouse.	
M		Genes Dev., 12: 3168-3181, 1998	

Examine Signature	9 11000	nesiles	Date Considered	3/23/2006

<sup>&</sup>quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	te for form 1449/PTO		<u> </u>		Complete if Known
				Application Number	10/809,312
INF	ORMATION	DIS	CLOSURE	Filing Date	03/24/04
STA	STATEMENT BY APPLICANT		First Named Inventor	Lloyd A. Greene	
	(lies on many sha			Art Unit	1636
	(Use as many sheets as necessary)			Examiner Name	tobe assigned Laura McG, LLEM
Sheet	9	of	12	Attorney Docket Number	5199-69

		NON PATENT LITERATURE DOCUMENTS	•
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Th		Moll et al., Attractive interhelical electrostatic interactions in the proline- and acidic-rich region (PAR) leucine zipper subfamily preclude	
Sh		preclude heterodimerization with other basic leucine zipper subfamilies.	
Sh		J. Biol. Chem., 275: 34826-34832, 2000	
Sh		Nikolae et al., Parc. A cytoplasmic anchor for p53.	
M		Cell, 112: 29-40, 2003,	
Fh		Nishizawa and Nagata, cDNA clones encoding leucine-zipper proteins which interact with G-CSF gene promoter element 1- binding protein.	
M	•	FEBS Lett., 299: 36-38, 1992,	
AM		Pati et al., Human Cdc34 and Rad6B ubiquitin-conjugating enzymes target repressors of cyclic AMP-induced transcription for proteolysis.	
Th		Mol. Cell Biol., 19: 5001-5013, 1999.	

Examiner Signature Lana he	Selly Date Considered	3/23/2006
----------------------------	-----------------------	-----------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	te for form 1449/PTO				Complete if Known
000000	10 10 10 11 17 10 1			Application Number	10/809,312
INF	ORMATION	DIS	SCLOSURE	Filing Date	03/24/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Lloyd A. Greene
	(Use as many she			Art Unit	1636
	(USB as many sne	rets as r	iocossary)	Examiner Name	to be assigned LAURA McGILLEM
Sheet	10	of	12	Attorney Docket Number	5199-69

			NON PATENT LITERATURE DOCUMENTS		
	Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	4m		Persengiev et al., Inhibition of apoptosis by ATFx: a novel role for a member of the ATF/CREB family of mammalian bZIP transcription factors.		
	An		Genes Dev., 16: 1806-1814, 2002.		
	Ym		Peters et al., ATF-7, a novel bZIP protein, interacts with the PRL-1 protein-tyrosine phosphatase.		
	pm		J. Biol. Chem., 276: 13718-13726, 2001,		
	4h		Placzek and Furley, Patterning cascades in the neural tube. Neural development.		
	Im		Curr. Biol. 6: 526-529, 1996 .		
	Sh		Schuurmans and Guillemot, Molecular mechanisms underlying cell fate specification in the developing telencephalon.		
• .	The		Curr. Opin. Neurobiol., 12: 26-34, 2002,		
	Sh		Takemura et al., In situ localization of tau mRNA in developing rat brain.		
	M		Neuroscience, 44: 393-407, 1991		

Examiner Signature Sama Millen	Date Considered	3/23/2006
--------------------------------	--------------------	-----------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ite for form 1449/PTO				Complete if Known
Substitu	10 10/10/11/14-3// 10			Application Number	10/809,312
INF	ORMATION	I DIS	CLOSURE	Filing Date	03/24/04
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Lloyd A. Greene
	44			Art Unit	1636
	(Use as many she	ets as n	ecessary)	Examiner Name	to-be assigned Laura McG. LLEA
Sheet	11	of	12	Attorney Docket Number	5199-69

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Sh		Towbin et al., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.	
In		Proc. Natl. Acad. Sci. USA 76: 4350-4354, 1979 👗	·
Sh		Uchida et al., Direct isolation of human central nervous system stem cells.	
m		Proc. Natl. Acad. Sci. USA, 97: 14720-14725, 2000,	
Sm		Vinson et al., Dimerization specificity of the leucine zipper-containing bZIP motif on DNA binding: prediction and rational design.	
M		Genes Dev., 7: 1047-1058, 1993-	
the		Waxman and Bennett, Relative conduction velocities of small myelinated and nonmyelinated fibres in the central nervous system.	
Th		Nature New Biol., 238: 217, 1972	1
Th		Wilda et al., Killing of leukemic cells with a BCR/ABL fusion gene RNA interference (RNAi).	
/m		Oncogene, 21: 5716-5724, 2002,	

Examiner Signature Saina Medica Date Considered 3/23/2006
---

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTQ				n of information unless it contains a valid OMB control number.  Complete if Known
3003010	10 10 10 10 11 14-07-10			Application Number	10/809,312
INF	ORMATIO	N DIS	CLOSURE	Filing Date	03/24/04
STA	STATEMENT BY APPLICANT			First Named Inventor	Lloyd A. Greene
	##			Art Unit	1636
	(Use as many st	ieets as n	ecessary)	Examiner Name	to-be assigned Laura McG. LLEH
Sheet	12	of	12	Attorney Docket Number	5199-69

			NON PATENT LITERATURE DOCUMENTS	
	Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	Jun		Yin et al., AC133, a novel marker for human hematopoietic stem and progenitor cells.	
•	The		Blood, 90: 5002-5012, 1997,	
•	Sh		Yu et al., AC133-2, a novel isoform of human AC133 stem cell antigen.	
	AM		J. Biol. Chem., 277: 20711-20716, 2002.	
Jot ded			Beers and Berkow, eds., The Merck Manual of Diagnosis and Therapy, 17th ed.	
Jot ded borseder Jorded Jorded	d		Whitehouse Station, NJ: Merck Research Laboratories, 1999, Chap. 183	
orded	-		Bodansky, M., Principles of Peptide Synthesis, New York: Springer-Verlag New York, Inc., 1984  () ()	
Notuces	¥		Modern Techniques of Peptide and Amino Acid Analysis, New York: John Wiley & Sons, 1981 (人人)	

Examiner Signature	Laura milelle	Date Considered	3/23/2006
Cignature			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.